Category: News

Dr. Shephal Doshi

MD

Scientific Advisory Board

Dr. Shephal Doshi practices Cardiac Electrophysiology (EP) and management of arrhythmias. He specializes in interventional therapies for arrhythmias including atrial fibrillation and ventricular tachycardia. Dr. Doshi joined the Pacific Heart Institute in 2024 and soon became the Director of Cardiac EP and Pacing at Providence, Saint John’s Health Center. He is currently the Executive Director of the Minerd Heart and Vascular  Institute.

Dr. Doshi remains active in cutting edge ablation research involving different forms of ablation energy including laser, cryo, and radiofrequency. He has been a principal investigator (PI) in studies involving balloon and contact force sensing ablation for atrial fibrillation.

Vivek Reddy

MD

Scientific Advisory Board

Dr. Reddy is Director of Cardiac Arrhythmia Services for The Mount Sinai Hospital and the Mount Sinai Health System, and The Leona M. and Harry B. Helmsley Charitable Trust Professor of Medicine in Cardiac Electrophysiology at Icahn School of Medicine at Mount Sinai.

One of the nation’s premier cardiac electrophysiologists, Dr. Reddy leads a team of physician-scientists that are developing and testing advanced therapies for cardiac arrhythmias—including atrial fibrillation and ventricular tachycardias, the most common cause of sudden cardiac death.

Dr. Reddy’s pioneering clinical research is changing the way cardiac patients are treated and cured. Under his leadership, Mount Sinai is the lead investigator on several multinational clinical trials exploring new arrhythmia procedures and technologies.

Reinoud Knops

MD, PHD

Scientific Advisory Board

Dr. Reinoud Knops is a renowned device cardiologist and professor at Amsterdam UMC, specializing in cardiac rhythm management and electrophysiology. With over 190 peer-reviewed publications, Dr. Knops is a highly regarded leader in his field. He has authored several influential articles in prestigious journals, including the New England Journal of Medicine, where he has been the first author on multiple high-impact papers.

Dr. Knops is the principal investigator of the PRAETORIAN trial, a large, international, multi-center, investigator-initiated, randomized controlled trial comparing the efficacy of transvenous versus subcutaneous implantable cardioverter-defibrillator (ICD) therapy. His research focuses on advancing the understanding and treatment of arrhythmias, with particular emphasis on innovative approaches to device therapy.

In addition to his academic and clinical work, Dr. Knops serves as a medical advisor for leading medical device companies including Abbott, Boston Scientific, Medtronic, and several start-up companies. He is frequently invited to serve as a steering committee member and principal investigator for various clinical trials in the field of cardiac rhythm management. His contributions to the development of new technologies and therapies have had a significant impact on improving patient care and outcomes in the management of heart rhythm disorders.

Gary Gershony

MD, FACC, FAHA, FSCAI

Scientific Advisory Board

Dr. Gershony is Director of Cardiovascular Research, Education and Technology at John Muir Cardiovascular Institute, where he has established a successful TAVR program. Previously he was Director of the Cardiac Cath Lab and Interventional Cardiology at UC Davis.

Board certified in general and interventional cardiology, Dr. Gershony is a Fellow of the American College of Cardiology, the American Heart Association, and the Society for Cardiovascular Angiography and Interventions. He has authored over 100 manuscripts and abstracts in the field of cardiology and is a regularly invited faculty lecturer to the preeminent U.S. and international interventional cardiology conferences.

Dr. Gershony graduated from the University of Toronto Medical School where he completed his training in general cardiology. He subsequently completed a fellowship in interventional cardiology at Emory University under Andreas Grüntzig, the inventor of angioplasty.

Martin Burke

DO

Chief Medical Officer, AtaCor Medical

Dr. Burke leads a full-service private electrophysiology practice, with procedure privileges at several hospitals in the Chicago area. He is also Director of Research at the CorVita Science Foundation and an adjunct faculty member at the Academic Medical Center in Amsterdam. Previously, Dr. Burke was a professor of medicine at the University of Chicago.

Dr. Burke has served as clinical investigator in numerous industry-sponsored clinical trials, including Cameron Health’s pivotal trial study for the S-ICD System. Dr. Burke has focused interests in device-based therapies for patients with life-threatening cardiac arrhythmias and has extensive experience collaborating with industry to develop and evaluate new technologies. Both his research interests and experience are exceptionally aligned with AtaCor Medical’s objective to develop the world’s first implantable, extracardiac pacemaker.

Sean McGeehan

JD

General Counsel & Chief Financial Officer

Sean has over 20 years of experience in the life science and medical device industries. His collective corporate and patent experience is a tremendous asset to AtaCor Medical and has resulted in numerous U.S. and international patents specific to AtaCor’s technology.

Previously, at Cameron Health, Sean developed and executed an IP strategy for obtaining and leveraging global patent protection and avoiding IP risks for a novel subcutaneous implantable defibrillator system (S-ICD) and was responsible for raising a total of $228M in equity ($183M) and debt financing ($45M). He further provided counsel through all stages of Cameron Health’s growth, including venture capital financings, clinical and regulatory matters, and the company’s acquisition by Boston Scientific in 2012.

Sean has also worked as an attorney at multi-national law firms, (Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP and Brobeck, Phleger & Harrison, LLP), where he advised venture capital funds and venture capital-backed emerging companies on fundraising, governance, and investment activities.

Sean earned a BSc degree in Microbiology from The Ohio State University, a BSc degree in Chemistry from the University of Minnesota (Institute of Technology) and a J.D. from the University of Minnesota Law School.

Rick Sanghera

BSEE, MBA

President & Chief Executive Officer

Rick has spent over 25 years within the cardiac rhythm management industry, with roles at Guidant Corporation, Cameron Health, and Boston Scientific – including 10 years dedicated to the development of the world’s first subcutaneous implantable defibrillator system (S-ICD). His experience includes positions within R&D as well as field-based roles, creating a foundation that gives him a keen ability to develop novel products that simplify the user experience and improve outcomes for patients.

With a deep understanding of how medical devices must interface with healthcare institutions, physicians, and patients, Rick played a critical role at Cameron Health where he led development efforts on the algorithm used to determine when defibrillation shocks should be delivered or inhibited.

Rick has proven leadership in research and engineering, a history of cultivating worldwide physician-industry collaborations, and holds over 70 patents in the cardiac rhythm management field.

Rick earned a BSc degree in Electrical Engineering from the University of Washington and an MBA from Oxford.

ALAN MARCOVECCHIO

MSEE

Vice President of Regulatory and Quality

Alan has spent over 25 years in the medical device industry innovating new medical devices for patients and physicians. He has been involved in more than 20 FDA IDE and international clinical studies, ranging from early feasibility studies to pivotal clinical trials supporting global regulatory approvals of life-enhancing and life-saving medical devices. His experience includes tenure at Guidant Corporation, Zoll Medical, Boston Scientific, and Cameron Health, during which time he held diverse engineering, field representative, clinical, quality and regulatory leadership roles.

Alan’s professional efforts have contributed to the design, development, clinical evaluation, and production of numerous medical devices, predominantly for cardiac rhythm management. He has successfully led regulatory teams through original IDE and FDA Advisory Panel Track PMA processes to approval. His experience also includes serving sales organizations during the launch of new technologies, giving him critical perspective into the development of new, viable medical technologies.

As a co-founder and the Vice President of Clinical, Regulatory & Quality, Alan is well poised to help lead AtaCor Medical’s efforts to bring forward the latest advancement in extravascular lead systems for pacing and defibrillation applications.

Alan earned a BSc in Electrical Engineering and Applied Physics with a minor in music from Case Western Reserve University. He also obtained his MSc in Electrical Engineering with a minor in Physics from the University of Minnesota.